FindTrial
Sign In

JNJ-64619178

DRUG3 trials

Sponsors

Janssen-Cilag International NV, Janssen Research & Development, LLC

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsNon-Hodgkin LymphomaNon-Hodgkin lymphoma and chronic lymphocytic leukemia CancerProstatic Neoplasms, Castration-Resistant

Phase 1

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
CompletedNCT03573310
Janssen Research & Development, LLCMyelodysplastic Syndromes, Neoplasms, Non-Hodgkin Lymphoma +1
Start: 2018-07-13End: 2025-09-25Updated: 2025-12-18
A rollover study for continued study treatment and ongoing safety monitoring
RecruitingISRCTN87946208
Janssen-Cilag International NVNon-Hodgkin lymphoma and chronic lymphocytic leukemia Cancer
Start: 2024-12-31Target: 77Updated: 2025-03-31
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Enrolling by invitationNCT06788509
Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin +4
Start: 2024-12-30End: 2028-10-30Target: 120Updated: 2026-05-08

Related Papers

Inhibition of PRMT5 with JNJ-64619178 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptosis
Blood2025-11-03
Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies
Blood2024-11-051 citations
Abstract C089: PRMT5 as a novel druggable vulnerability for EWSR1-ATF1-driven clear cell sarcoma
Molecular Cancer Therapeutics2023-12-01
Inhibition of PRMT5 Increases Sensitivity to BH3 Mimetics in Aggressive B Cell Malignancies
Blood2022-11-151 citations